Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Fujiwara Y, et al. Among authors: sakiyama n. Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14. Cancer Sci. 2023. PMID: 36704833 Free PMC article.
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
Hibino H, Sakiyama N, Makino Y, Makihara-Ando R, Horinouchi H, Fujiwara Y, Kanda S, Goto Y, Yoshida T, Okuma Y, Shinno Y, Murakami S, Hashimoto H, Akiyoshi T, Imaoka A, Ohe Y, Yamaguchi M, Ohtani H. Hibino H, et al. Among authors: sakiyama n. Eur J Clin Pharmacol. 2022 Apr;78(4):613-621. doi: 10.1007/s00228-022-03275-5. Epub 2022 Jan 17. Eur J Clin Pharmacol. 2022. PMID: 35039908
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI, Yoshida T, Yagishita S, Ohuchi M, Sakiyama N, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Hamada A, Ohe Y. Higashiyama RI, et al. Among authors: sakiyama n. J Thorac Oncol. 2022 Oct;17(10):1227-1232. doi: 10.1016/j.jtho.2022.06.010. Epub 2022 Jul 3. J Thorac Oncol. 2022. PMID: 35788404 Free article.
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Egami S, et al. Among authors: sakiyama n. J Cancer. 2021 Feb 16;12(7):2105-2112. doi: 10.7150/jca.53242. eCollection 2021. J Cancer. 2021. PMID: 33754009 Free PMC article.
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study.
Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Egami S, et al. Among authors: sakiyama n. Front Oncol. 2021 May 27;11:618570. doi: 10.3389/fonc.2021.618570. eCollection 2021. Front Oncol. 2021. PMID: 34123782 Free PMC article.
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T. Ogiwara T, et al. Among authors: sakiyama n. Front Oncol. 2021 Nov 8;11:770268. doi: 10.3389/fonc.2021.770268. eCollection 2021. Front Oncol. 2021. PMID: 34820333 Free PMC article.
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Arami T, Kawazoe H, Uozumi R, Hashimoto H, Egami S, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Yasuda H, Kawada I, Fukunaga K, Soejima K, Yamaguchi M, Nakamura T. Arami T, et al. Among authors: sakiyama n. Pharmazie. 2021 Jun 1;76(6):266-271. doi: 10.1691/ph.2021.1409. Pharmazie. 2021. PMID: 34078521
Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study.
Satomi E, Kobayashi T, Ishikawa A, Arakawa S, Ishiki H, Amano K, Sakiyama N, Ariyoshi K, Kihara K, Oyamada S, Mizushima A. Satomi E, et al. Among authors: sakiyama n. BMJ Open. 2024 Feb 27;14(2):e076575. doi: 10.1136/bmjopen-2023-076575. BMJ Open. 2024. PMID: 38417963 Free PMC article.
60 results